ArticleMolecular genetics and genomics : MGG2026
Impairment of ribosomes and DNA biosynthesis confers resistance to Inhibition of sphingolipid biosynthesis.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mannosylinositol Phosphorylceramide Biosynthesis Is Required for Cell Surface Adaptation to Ethanol Stress in Saccharomyces cerevisiae.Molecular microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingolipids are essential components of eukaryotic membranes and play central roles in cellular growth and stress responses. In the budding yeast Saccharomyces cerevisiae, Lcb1 and Lcb2 constitute the serine palmitoyltransferase complex, which catalyzes the initial step of sphingolipid biosynthesis. Repression of LCB1 expression leads to inhibition of sphingolipid biosynthesis, resulting in severe growth defects. Here, we aimed to identify novel genes functionally associated with sphingolipid metabolism by screening for suppressor mutations that confer resistance to sphingolipid biosynthesis inhibition. To conditionally suppress sphingolipid biosynthesis, we employed a tetracycline-repressible promoter to control LCB1 expression. This screen revealed that deletion of SAC7, YTA7, RNR1, RPL23B, or RPL35A confers resistance to LCB1 repression. The suppressive effect of YTA7, RNR1, RPL23B, and RPL35A deletions was also observed under conditions in which growth inhibition was induced by repression of AUR1, a gene involved in the conversion of ceramides to complex sphingolipids. These genes encode proteins related to ribosomal subunits or DNA biosynthesis. Furthermore, sublethal concentrations of cycloheximide (a translation inhibitor), diazaborine (a ribosome maturation inhibitor), hydroxyurea (a DNA biosynthesis inhibitor), and zeocin (a DNA double-strand break inducer) alleviated growth defects caused by LCB1 repression. Diazaborine or hydroxyurea partly suppressed the decrease in complex sphingolipids induced by Lcb1 repression. Additionally, these treatments suppressed the reduction in Lcb1 and Aur1 protein expression levels. These findings reveal a previously unappreciated link between ribosome function, DNA biosynthesis, and sphingolipid metabolism and provide insight into how cells adapt to metabolic stress.
Indexed as
Identifiers
41619027What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.